Aquabounty Technologies Inc: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 7, 2023 and accepted by EDGAR at Nov 7, 2023, 08:13 ET.
Management's discussion and analysis
As filed, 18,329 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed on March 7, 2023.
Overview
We believe that we are a distinctive brand in the field of land-based aquaculture, leveraging decades of technology expertise to deliver innovative solutions that address food insecurity and climate change issues, while improving efficiency and sustainability. We provide fresh Atlantic salmon to nearby markets by raising our fish in carefully monitored land-based fish farms through a safe, secure and sustainable process. Our land-based Recirculating Aquaculture System farms, including our grow-out farm located in Indiana in the United States and our broodstock and egg production farm located on Prince Edward Island in Canada, are close to key consumption markets and are designed to prevent disease and to include multiple levels of fish containment to protect wild fish populations. We are raising nutritious salmon that is free of antibiotics and other contaminants and provides a solution with a reduced carbon footprint without the risk of pollution to marine ecosystems as compared to traditional sea-cage farming. Our primary product is our GE Atlantic salmon, which received FDA approval in 2015 as the first genetically engineered animal available for sale for human consumption. We commenced commercial activities in 2021 with operations in the United States and Canada. We are actively engaged in genetic, genomic, fish health and fish nutrition research, which drive continuous improvement in our operations and may lead to new, disruptive technologies and products that could further expand our competitive offerings.
Inflation
Recently elevated global inflation rates continue to impact all areas of our business. We are experiencing higher costs for farming supplies, transportation costs, wage rates, and other direct operating expenses, as well as for capital expenditures related to the construction of our farm in Ohio. We expect inflation to continue to negatively impact our results of operations for the near-term.
Revenue
We currently generate product revenue through the sales of our GE Atlantic salmon, conventional Atlantic salmon eggs and fry, and salmon byproducts. We measure our harvest volume of GE Atlantic salmon in terms of metric tons (“mt”) of live weight taken out of the water. We believe that our future revenues will depend upon the number and capacity of grow-out farms we have in operation and the market acceptance we achieve.
Product Costs
Product costs include the labor and related costs to grow out our fish, including feed, oxygen, and other direct costs; overhead; and the cost to process and ship our products to customers. A portion of production costs is absorbed into inventory as fish in process to the extent that these costs do not exceed the net realizable value of the fish biomass. The costs that are not absorbed into inventory, as well as any net realizable value inventory adjustments, are classified as product costs. Our product costs also include the labor and related costs to maintain our salmon broodstock.
Sales and Marketing Expenses
Our sales and marketing expenses currently include salaries and related costs for our sales personnel and consulting fees for market-related activities. We expect our sales and marketing expenses to increase as our production output and revenues grow.
Research and Development Expenses
We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:
salaries and related overhead expenses for personnel in research and development functions;
fees paid to contract research organizations and consultants who perform research for us;
costs related to laboratory supplies used in our research and development efforts; and
costs related to the operation of our field trials.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs for employees in executive, corporate, and finance functions. Other significant general and administrative expenses include corporate governance and public company costs, regulatory affairs, rent and utilities, insurance, and legal services.
Other Expense
Interest expense includes the interest on our outstanding loans and the amortization of debt issuance costs. Other income includes interest income, less bank charges, fees, miscellaneous gains or losses on asset disposals and realized gains or losses on investments.
Results of Operations
Comparison of the three months ended September 30, 2023, to the three months ended September 30, 2022
The following table summarizes our results of operations for the three months ended September 30, 2023 and 2022, together with the changes in those items in dollars and as a percentage (all dollar amounts in thousands):
(unaudited)
| Three Months Ended September 30, 2023 | 2022 | Dollar% Change | Change | |
|---|---|---|---|---|
| Product revenue | $733 | $653 | 80 | 12% |
| Operating expenses: | ||||
| Product costs | 4,096 | 3,518 | 578 | 16% |
| Sales and marketing | 192 | 186 | 6 | 3% |
| Research and development | 184 | 221 | (37) | (17)% |
| General and administrative | 2,335 | 2,265 | 70 | 3% |
| Operating loss | 6,074 | 5,537 | 537 | 10% |
| Total other expense (income) | 64 | (97) | 161 | (166)% |
| Net loss | $6,138 | $5,440 | 698 | 13% |
Product Revenue
(unaudited)
| Three Months Ended September 30,% 2023 | 2022 | Change | Change | |
|---|---|---|---|---|
| Harvest of GE Atlantic salmon (mt) | 144 | 103 | 41 | 40% |
| Product revenue | ||||
| GE Atlantic salmon revenue | $632 | $594 | $38 | 6% |
| Non-GE Atlantic salmon revenue | 89 | 48 | 41 | 85% |
| Other revenue | 12 | 11 | 1 | 9% |
| Total product revenue | $733 | $653 | $80 | 12% |
The increase in revenue during the current period was primarily due to an increase in harvest volume of our GE Atlantic salmon, which was partially offset by a decline in market prices. Additionally, sales of conventional eggs and fry from the Rollo Bay farm were higher in the current period due to demand. We expect revenues for the remainder of 2023 to be impacted by normal seasonal demand and fluctuating market prices.
Product Costs
Product costs for the three months ended September 30, 2023, were up from the corresponding period in 2022, due to a combination of a higher level of biomass at the Indiana farm, personnel costs, feed costs, other direct supplies, and product disposals.
Sales and Marketing Expenses
Sales and marketing expenses for the three months ended September 30, 2023, were up slightly from the corresponding period in 2022 due to increases in personnel costs and marketing programs, offset by a decrease in travel.
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2023 were down from the corresponding period in 2022 primarily due to decreases in project spending.
General and Administrative Expenses
General and administrative expenses for the three months ended September 30, 2023, were up from the corresponding period in 2022 with increases in state excise tax liabilities and legal fees, offset by reductions in professional services and recruitment fees.
Total Other Expense
Total other expense is comprised of interest on debt and bank charges, less interest income for the three months ended September 30, 2023, and 2022.
Comparison of the nine months ended September 30, 2023, to the nine months ended September 30, 2022
The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2022, together with the changes in those items in dollars and as a percentage (all dollar amounts in thousands):
(unaudited)
| Nine Months Ended September 30, 2023 | 2022 | Dollar% Change | Change | |
|---|---|---|---|---|
| Product revenue | $1,919 | $2,686 | (767) | (29)% |
| Operating expenses: | ||||
| Product costs | 11,446 | 10,044 | 1,402 | 14% |
| Sales and marketing | 584 | 784 | (200) | (26)% |
| Research and development | 486 | 596 | (110) | (18)% |
| General and administrative | 8,403 | 7,473 | 930 | 12% |
| Operating loss | 19,000 | 16,211 | 2,789 | 17% |
| Total other expense (income) | 133 | (123) | 256 | (208)% |
| Net loss | $19,133 | $16,088 | 3,045 | 19% |
Product Revenue
(unaudited)
| Nine Months Ended September 30,% 2023 | 2022 | Change | Change | |
|---|---|---|---|---|
| Harvest of GE Atlantic salmon (mt) | 369 | 365 | 4 | 1% |
| Product revenue | ||||
| GE Atlantic salmon revenue | $1,779 | $2,535 | $(756) | (30)% |
| Non-GE Atlantic salmon revenue | 124 | 128 | (4) | (3)% |
| Other revenue | 16 | 23 | (7) | (30)% |
| Total product revenue | $1,919 | $2,686 | $(767) | (29)% |
The decrease in revenue during the current period was due primarily to product mix and decreases in market prices of our GE Atlantic salmon. The change in product mix was the result of repairs to our processing facility during the first five months of the current year, which impacted our ability to process fish on-site. Sales of conventional eggs and fry from the Rollo Bay farm were slightly lower in the current period due to market demand. We expect revenues for the remainder of 2023 to be impacted by normal seasonal demand and fluctuating market prices.
Product Costs
Product costs for the nine months ended September 30, 2023, were up from the corresponding period in 2022, due to a higher level of biomass at the Indiana farm, personnel costs, feed costs and other direct supplies. Additionally, costs were impacted by repairs to the processing facility at our Indiana farm.
Sales and Marketing Expenses
Sales and marketing expenses for the nine months ended September 30, 2023, were down from the corresponding period in 2022 due to decreases in marketing programs and travel.
Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2023 were down from the corresponding period in 2022 primarily due to the receipt of provincial government grant funds in support of local hiring. Gross research and development expenses for the current period, excluding the grant funds were $598 thousand versus $627 thousand in the corresponding period in 2022.
General and Administrative Expenses
General and administrative expenses for the nine months ended September 30, 2023, were up from the corresponding period in 2022 due to an increase in state excise tax liabilities, legal fees, and personnel costs offset by a decrease in recruitment costs.
Total Other Expense
Total other expense is comprised of interest on debt and bank charges, less interest income for the nine months ended September 30, 2023, and 2022.
Cash Flows
The following table sets forth the significant sources and uses of cash for the periods set forth below (in thousands):
(unaudited)
| Net cash (used in) provided by: | Nine Months Ended September 30, 2023 | 2022 | Dollar% Change | Change |
|---|---|---|---|---|
| Operating activities | $(18,462) | $(17,953) | (509) | 3% |
| Investing activities | (66,260) | 56,944 | (123,204) | (216)% |
| Financing activities | (148) | (435) | 287 | (66)% |
| Effect of exchange rate changes on cash | (1) | (2) | 1 | (50)% |
| Net change in cash | $(84,871) | $38,554 | (123,425) | (320)% |
Cash Flows from Operating Activities
Net cash used in operating activities during the nine months ended September 30, 2023, was primarily comprised of our $19.1 million net loss, offset by non-cash depreciation and stock compensation charges of $2.0 million and increased by working capital uses of $1.4 million. Net cash used in operating activities during the nine months ended September 30, 2022, was primarily comprised of our $16.1 million net loss, offset by non-cash depreciation and stock compensation charges of $1.9 million and increased by working capital uses of $3.8 million.
Spending on operations increased in the current period due to increases in state excise tax liabilities, legal fees, compensation costs and production activities at our Indiana farm site. Cash used by working capital decreased in the current period primarily due to decreases in receivables, inventory, accounts payable and accrued expenses.
Cash Flows from Investing Activities
During the nine months ended September 30, 2023, we used $66.3 million for construction activities at our farm sites and the purchase of equipment. During the same period in 2022, we used $44.9 million for construction activities at our farm sites and the purchase of equipment, offset by cash provided by the net sale of marketable securities of $101.8 million.
Cash Flows from Financing Activities
During the nine months ended September 30, 2023, we received $394 thousand from new debt and made $542 thousand in debt repayments. During the same period in 2022, we received $42 thousand from new debt and made $479 thousand in debt repayment.
Future Capital Requirements
Since inception, we have incurred cumulative net operating losses and negative cash flows from operations and we expect this to continue for the foreseeable future. As of September 30, 2023, we had $17.8 million in cash and cash equivalents, and restricted cash, a significant portion of which is required to fund our current liabilities and other contractual obligations. Our ability to continue as a going concern is dependent upon our ability to raise additional capital, and there can be no assurance that such capital will be available in sufficient amounts on terms acceptable to us, or at all. This raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued.
Until such time, if ever, as we can generate positive operating cash flows, we may finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of holders of our common stock will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through government or other third-party funding; marketing and distribution arrangements; or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us.
If we are unable to generate additional funds in the future through financings, sales of our products, government grants, loans, or from other sources or transactions, we will exhaust our resources and will be unable to maintain our currently planned operations. If we cannot continue as a going concern, our stockholders would likely lose most or all of their investment in us.
Critical Accounting Policies and Estimates
Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which we have prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to these estimates, or the policies related to them, during the nine months ended September 30, 2023. For a full discussion of these estimates and policies, see “Critical Accounting Policies and Estimates” within “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022.
Smaller Reporting Company Status
We are a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million.
As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and smaller reporting companies have reduced disclosure obligations regarding executive compensation.
Market risk
As filed, 1,563 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following sections provide quantitative information on our exposure to interest rate risk and foreign currency exchange risk. We make use of sensitivity analyses, which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.
Interest Rate Risk
Our primary exposure to market risk is interest rate risk associated with debt financing that we utilize from time to time to fund operations or specific projects. The interest on this debt is usually determined based on a fixed rate and is contractually set in advance. As of September 30, 2023, and December 31, 2022, we had $4.7 million and $5.1 million, respectively, in interest-bearing debt instruments on our consolidated balance sheet. All of our interest-bearing debt is at fixed rates, except for our loan with First Farmers’ Bank and Trust which has a rate reset in July 2025.
Foreign Currency Exchange Risk
Our functional currency is the U.S. Dollar. The functional currency of our Canadian subsidiary is the Canadian Dollar, and the functional currency of our U.S. and Brazil subsidiaries is the U.S. Dollar. For the Canadian subsidiary, assets and liabilities are translated at the exchange rates in effect at the balance sheet date, equity accounts are translated at the historical exchange rate, and the income statement accounts are translated at the average rate for each period during the year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive loss within shareholders’ equity.
Controls and procedures
As filed, 1,504 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the quarter ended September 30, 2023, the Company’s disclosure controls and procedures are effective in recording, processing, summarizing, and reporting, on a timely basis, information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act and are effective in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 12,448 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed on March 7, 2023, there are a number of risk factors that could affect our business, financial condition, and results of operations. The following risk factors are either new or have changed materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2022, our 10-Q for the quarter ended March 31, 2023, or our 10-Q for the quarter ended June 30, 2023. In evaluating our business, you should carefully review the risks described in our Annual Report on Form 10-K, including our consolidated financial statements and related notes, and in other reports we file with the Securities and Exchange Commission. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition, or prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.
This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks faced by us described below, elsewhere in this Quarterly Report on Form 10-Q, and in our Annual Report on Form 10-K. See “Cautionary Note Regarding Forward-Looking Statements” for information relating to these forward-looking statements.
We have a history of net losses and will likely incur future losses and may not achieve or maintain profitability.
In the period from incorporation to September 30, 2023, we have incurred cumulative net losses of approximately $212 million. These losses reflect our personnel, research and development, production and marketing costs. Our ability to realize revenues and the timing thereof are not certain, and achieving revenues does not assure that we will become profitable. We anticipate incurring additional losses until such time that we can generate significant increases to our revenues, and/or reduce our operating costs and losses. The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to significantly grow our business and increase our revenues. We expect to continue to incur substantial and increased expenses as we grow our business. We also expect a continued increase in our expenses associated with our operations as a publicly traded company.
As of September 30, 2023, we had $17.8 million in cash and cash equivalents, and restricted cash, a significant portion of which is required to fund current liabilities and other contractual obligations. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and there can be no assurance that such capital will be available in sufficient amounts, on terms acceptable to us, or at all. As a result of the going concern uncertainty, there is an increased risk that our investors could lose some or all of their investment in our company.
Our business plans include the need for substantial additional capital and without it we may not be able to implement our strategy as planned or at all.
Our current strategy depends on our ability to develop and construct additional farms, including our planned Ohio farm. We have begun construction of this farm and its construction, and others in the future, are contingent on a number of significant uncertainties, including those described below. As a result, we may be unable to construct such facilities as planned or at all. We may not be able to obtain the financing necessary to complete construction of our proposed facilities. We estimate that the total project cost for the Ohio farm, including construction, land, insurance and ancillary costs will be in the range of $485 million to $495 million, substantially above our previously disclosed range of between of $375 million to $395 million, although this figure could continue to change as we finalize the design, finalize bids from contractors and continue with construction. For example, at least partially due to recent inflationary pressures, subcontractors for certain goods and services at our Ohio farm have submitted bids above the levels that we expected. As a result of these increases, and increased interest rates, we have raised our estimate for the total cost for the project and we increased the amount of proposed debt financing. However, there can be no guarantee that our attempts will be successful, and macro-economic conditions could worsen, which could result in further cost increases and further financing and construction-related delays. Recent increases in the construction cost estimate have caused us to put construction on pause until we can evaluate the completion cost estimate and our financing strategy.
We do not have the financial resources required to fully finance the construction of the Ohio farm. We will seek to raise part of these necessary funds through debt financing. Recent increases in interest rates have increased the borrowing costs for this financing, and any further increases before the financing is complete could further increase such costs. Volatility and/or declines in equity markets in general, and for our securities, may cause equity financing to be unavailable on acceptable terms or at all. We may also need further funding if there are delays in construction or increased construction costs at our construction site in Ohio. We may finance unanticipated construction costs by issuing equity securities or debt. The delay or failure of regulatory bodies to approve our construction plans, disruption and volatility in the financial markets, tighter credit markets and a downturn in the seafood market may negatively impact our ability to obtain financing. We may not have access to the required funding, or funding may not be available to us on acceptable terms.
We may not be able to obtain the approvals and permits that will be necessary in order to construct and operate our facilities as planned. We will need to obtain a number of required permits in connection with the hydrology, construction and operation of our farms, which is often a time-consuming process. For example, through the Village of Pioneer, we currently are pursuing an application to Williams County for a permit to install transmission lines through an existing right-of-way controlled by Williams County that would carry raw water from our permitted well to our Ohio farm location, and a wastewater/stormwater line that would return treated water from the farm to a discharge location. Williams County denied our requests and we and the Village of Pioneer have filed appeals with the Court of Common Pleas in Williams County, Ohio. We will also need to obtain FDA approval to grow our GE Atlantic salmon in the facility. Delays or conditions imposed in obtaining the required approvals and permits for our farms, have and may further delay our expected construction completion, commercial stocking and first sale dates and/or lead to further cost increases. If we are unable to obtain the required approvals and permits for our farms, we will not be able to construct the farms. In addition, federal, state and local governmental requirements could substantially increase our costs, which could materially harm our results of operations and financial condition.
We have encountered cost increases in the expected construction cost of the Ohio farm, and may encounter further unanticipated difficulties and cost overruns in constructing this farm and other future farms. Preparing cost and timing estimates for complex RAS farms is inherently difficult and subject to change based on a number of factors that we have experienced to date and may experience in the future, including design changes, increasing inflationary pressure on costs of materials and labor, the impact of health epidemics such as COVID-19, construction delays, dependence on contractors, the impact of increasing interest rates on financing costs, customer requirements and unexpected complications. As a result, we may encounter unanticipated difficulties and the construction and development of our proposed farms may be more costly or time-consuming than we anticipate.
Delays and defects may cause our costs to increase to a level that would make one or more of our farms too expensive to construct or unprofitable. We may suffer significant delays or cost overruns at our farms that could prevent us from commencing operations as expected as a result of various factors. These factors include shortages of workers or materials, construction and equipment cost escalation, transportation constraints, adverse weather, unforeseen difficulties or labor issues, or changes in political administrations at the federal, state or local levels that result in policy change towards genetically engineered foods in general or our products and farms in particular. Defects in materials or workmanship could also delay the commencement of operations of our planned farms, increase production costs or negatively affect the quality of our products. Due to these or other unforeseen factors, we may not be able to proceed with the construction or operation of our farms in a timely manner or at all.
We may not be able to maintain our listing on NASDAQ which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.
Even though our common stock is traded on the Nasdaq Capital Market, we cannot assure you that we will be able to comply with standards necessary to maintain such listing, which may result in our common stock being delisted from the Nasdaq Capital Market. If our common stock were no longer listed on the Nasdaq Capital Market, investors would experience impaired liquidity for our common stock, not only in the number of shares that could be bought and sold at a given price, which might be depressed by the relative illiquidity, but also through delays in the timing of transactions and reduction in media coverage. For example, investors might only be able to trade on one of the over-the-counter markets. In addition, we could face significant material adverse consequences, including:
a limited availability of market quotations for our securities;
a limited amount of news and analyst coverage for us; and
a decreased ability to issue additional securities or obtain additional financing in the future.
On October 31, 2022, we received a letter (the “Notice”) from The NASDAQ Stock Market LLC (“Nasdaq”) notifying us that, because the closing bid price for our common stock, par value $0.001 per share, had been below $1.00 per share for the previous 30 consecutive business days, it no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Notice had no immediate effect on our listing on the Nasdaq Capital Market or on the trading of our Common Stock. The Notice provided us with a compliance period of 180 calendar days, or until May 1, 2023, to regain compliance. We were unable to regain compliance with the bid price requirement by May 1, 2023. However, on May 2, 2023, we received a notice from Nasdaq granting us an additional 180 calendar days, or until October 30, 2023, to regain compliance with the minimum $1.00 bid price per share requirement for continued listing on the Nasdaq Capital Market.
To improve the price level of our common stock so that we could regain compliance with the minimum bid price requirement, on October 12, 2023, our stockholders approved a reverse stock split of our common stock and our Board of Directors approved a split ratio of 1-for-20. The reverse stock split was implemented on October 16, 2023 and on October 30, 2023, we received a notice from Nasdaq confirming that we had regained compliance with the minimum bid price requirement.
There can be no assurance that we will maintain compliance with the listing requirements. If we fail in the future to comply with Nasdaq listing rules, it could lead to the delisting of our common stock from Nasdaq and our common stock trading, if at all, only on the over-the-counter markets.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $733.1k | us-gaap:Revenues |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $1.9m | us-gaap:Revenues |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $184.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $485.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$6.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-01 to 2023-09-30 | −$19.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-07-01 to 2023-09-30 | $63.7k | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | $195.8k | us-gaap:InterestExpense |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$6.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$19.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | −$1.60 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | −$4.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | −$1.60 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | −$4.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 3,846,622 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 3,843,349 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | −$18.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $66.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-09-30 | $16.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $22.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $192.5m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $11.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $19.4m | us-gaap:Liabilities |
| Long-term debt | At period end2023-09-30 | $7.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-09-30 | $756.6k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-09-30 | $173.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001603978-23-000060. Last ingested by Listed: Nov 6, 2026, 16:32 ET. Listed shows no prices and gives no investment advice.